← All trials
NCT06213987
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2024
- Primary completion
- Jun 1, 2024
- Completion date
- Jun 1, 2024
- First posted
- Jan 19, 2024
- Last posted
- Aug 13, 2024
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Srinakharinwirot UniversityLead sponsor
- Srinakharinwirot UniversitySponsor investigator
- Srinakharinwirot UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.